New combo targets tough breast cancer in early trial

NCT ID NCT04253561

First seen Mar 24, 2026 · Last updated May 16, 2026 · Updated 3 times

Summary

This early-phase study tested a new combination of drugs for people with a specific type of advanced breast cancer (HER2-positive with a PIK3CA mutation). The goal was to find the safest dose of the new drug (ipatasertib) when added to two standard treatments. Only 17 people took part, and the focus was on safety and finding the right dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centro Integral Oncológico Clara Campal (CIOCC)

    Madrid, Madrid, Spain

  • Comp. Hosp.Univ. Santiago (Chus)

    Santiago de Compostela, La Coruña, Spain

  • Fundación Instituto Valenciano de Oncología

    Valencia, Valencia, Spain

  • H.Univ. Arnau de Vilanova de Lleida

    Lleida, Lleida, Spain

  • Hospital Universitario Doce de Octubre

    Madrid, Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Sevilla, Spain

  • Hospital Universitario del Vall d' Hebron

    Barcelona, Barcelona, Spain

  • Hospital Virgen de Macarena

    Seville, Sevilla, Spain

  • ICO Badalona

    Badalona, Barcelona, Spain

  • MD Anderson

    Madrid, Madrid, Spain

Conditions

Explore the condition pages connected to this study.